Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Nektar TherapeuticsNASDAQ: NKTR

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income dips below year-ago levels

Q2 FY2026 net income of $40.62M (cash outflow) fell 2.3% year over year, behind the +28.5% change in trailing-twelve-month net income. Sequentially, it fell 9.5% from the prior quarter. Over 3 fiscal years it compounded at -23.6% a year.

Context

  • Net income amounted to 297.1% of revenue in FY2025, up 176.2 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 13 analysts of -$127.28M (-22.4%) for the fiscal year ending Dec 2026, a slowdown from the +37.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$40.62M-9.5% QoQ
Last fiscal yearDec 2025
-$164.08M+37.9% YoY
LTMJun 2026
-$157.13M+28.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.3%+99.1%+101.4 pp
1 year+37.9%-22.4%-60.4 pp
3-year CAGR-23.6%-2.2%+21.4 pp
5-year CAGR-12.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(164.08M) USD
Year-over-year change
-37.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +28.5% is the 5th highest of 9, against a peer median of +27.4%.
  • Net income amounts to 287.8% of revenue for NKTR, versus a peer median of 393.2%.
NKTR Competitors
Net Income for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHRSCoherus Oncology, Inc.LTM Mar 2026$465.5M USD+369.3%—992.9%
RCUSArcus Biosciences, Inc.LTM Jun 2026$460M USD+54.4%+9.8%393.2%
IMTXImmatics N.V.LTM Mar 2026€217.14M EUR+906.0%—582.2%
NKTRNektar TherapeuticsLTM Jun 2026$157.13M USD+28.5%-23.6%287.8%
XNCRXencor, Inc.LTM Jun 2026$71.19M USD-60.8%+18.5%67.8%
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
ANLAdlai Nortye Ltd.LTM Jun 2024$54.07M USD—-15.4%833.1%
IPHAInnate Pharma S.A.FY2025€49.18M EUR-0.6%-5.4%1764.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$44.17M USD+6.7%-28.2%—
CGENCompugen Ltd.LTM Dec 2025$35.34M USD——48.6%
IMCRImmunocore Holdings plcLTM Mar 2026$27.59M USD+28.8%-20.5%7.2%
Peer median (excluding NKTR) —+27.4%-14.6%393.2%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Depreciation & Amortization14.15M13.03M7.82M4.39M(4.49M)
Deferred Income Tax8.02M2.71M(140K)00
Stock-Based Compensation94.67M57.32M33.39M21.61M12.65M
Change in Working Capital(23.08M)492K(19.8M)(6.24M)(37.02M)
Accounts Receivables12.4M16.51M4.78M(3.05M)0
Inventory(509K)(3.4M)699K497K0
Accounts Payables(11.69M)3.1M(2.88M)2.67M(625K)
Other Working Capital(23.27M)(15.72M)(22.39M)(6.36M)(36.39M)
Other Non-Cash Items17.41M(9.36M)62.19M(76.51M)(15.58M)
Operating Cash Flow(412.66M)(304.01M)(192.61M)(175.71M)(208.51M)
Capital Expenditures(14.99M)(5.68M)(865K)(1.47M)(171K)
Acquisitions (Net)(217.77M)13.2M065.39M(697K)
Purchases of Investments(960.69M)(467.91M)(511.7M)(261.71M)(285.01M)
Sales of Investments1.18B826.23M650.88M340.36M284.68M
Other Investing Activities217.77M01.25M00
Investing Cash Flow202.78M365.84M139.56M142.57M(1.2M)
Debt Repayment00000
Common Stock Issued33.24M758K30K30.12M180.57M
Common Stock Repurchased000(3M)0
Dividends Paid00000
Other Financing Activities3M750K015M0
Financing Cash Flow36.24M1.51M30K42.12M180.57M
Effect of Forex Changes(92K)(327K)62K(4K)6K
Net Change in Cash(173.74M)63.01M(52.95M)8.98M(29.14M)
Free Cash Flow(427.65M)(309.68M)(193.47M)(177.18M)(208.68M)

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.